Table 2.
Differentially expressed microRNA among pooled reduction mammoplasty, histologically normal and ductal carcinoma in situa
| HN versus PRM | DCIS versus PRM | DCIS versus HN | ||||
|---|---|---|---|---|---|---|
| microRNA | Fold change | P valueb | Fold change | P valueb | Fold change | P valueb |
| let-7c [62] | 15.23 | 3.46E-03c | 0.31 | 1.25E-01 | 0.03 | 1.19E-03c |
| miR-7 [38] | 3.12 | 1.35E-01 | 22.35 | 1.53E-03c | 5.19 | 4.92E-02 |
| miR-10b [13,39] | 2.90 | 1.59E-01 | 0.82 | 7.82E-01 | 0.04 | 2.58E-03c |
| miR-17-3p [32,40] | 19.04 | 2.14E-03c | 2.20 | 2.85E-01 | 0.12 | 1.73E-02 |
| miR-18a [34] | 1.91 | 3.76E-01 | 20.88 | 1.76E-03c | 3.53 | 1.12E-01 |
| miR-21 [13,31,36,40,41] | 6.74 | 2.23E-02 | 55.20 | 2.64E-04c | 20.92 | 3.21E-03c |
| miR-93[34] | 7.53 | 1.72E-02 | 193.86 | 3.33E-05d | 160.47 | 1.59E-04d |
| miR-99a | 1.90 | 3.79E-01 | 0.53 | 3.79E-01 | 0.02 | 9.19E-04c |
| miR-99b | 3.08 | 1.39E-01 | 14.84 | 3.66E-03c | 6.24 | 3.33E-02 |
| miR-125b [13,29] | 0.93 | 9.24E-01 | 0.08 | 5.39E-03c | 0.05 | 4.03E-03c |
| miR-127 [30,31] | 1.77 | 4.30E-01 | 0.25 | 7.81E-02 | 0.02 | 5.30E-04c |
| miR-130a | 0.29 | 1.06E-01 | 0.01 | 1.38E-04d | 0.09 | 1.01E-02 |
| miR-145 [13,14] | 3.00 | 1.47E-01 | 0.80 | 7.52E-01 | 0.03 | 1.20E-03c |
| miR-181b [31,40] | 3.40 | 1.11E-01 | 14.90 | 3.64E-03c | 5.46 | 4.42E-02 |
| miR-182 [33] | 2.00 | 3.45E-01 | 106.24 | 8.54E-05d | 72.35 | 4.55E-04c |
| miR-183 | 2.52 | 2.15E-01 | 19.06 | 2.14E-03c | 51.88 | 7.38E-04c |
| miR-191 [13] | 6.75 | 2.23E-02 | 78.21 | 1.43E-04d | 31.59 | 1.60E-03c |
| miR-193b [18] | 2.20 | 2.84E-01 | 15.67 | 3.25E-03c | 6.87 | 2.73E-02 |
| miR-195 [35] | 1.37 | 6.57E-01 | 0.06 | 2.78E-03c | 0.13 | 2.15E-02 |
| miR-200b [37] | 1.70 | 4.63E-01 | 6.07 | 2.86E-02 | 51.31 | 7.50E-04c |
| miR-200c [37] | 1.90 | 3.80E-01 | 26.41 | 1.08E-03c | 19.98 | 3.48E-03c |
| miR-204 [13] | 0.77 | 7.12E-01 | 0.04 | 1.32E-03c | 0.08 | 8.12E-03c |
| miR-324-5p | 2.86 | 1.64E-01 | 24.38 | 1.28E-03c | 92.53 | 3.24E-04c |
| miR-365 [31] | 4.05 | 7.45E-02 | 17.65 | 2.51E-03c | 25.05 | 2.35E-03c |
| miR-376a | 0.45 | 2.73E-01 | 0.06 | 3.14E-03c | 0.24 | 7.91E-02c |
| miR-382 | 2.03 | 3.32E-01 | 0.11 | 1.20E-02c | 0.06 | 4.71E-03c |
| miR-383 [34] | 0.05 | 2.15E-03c | 0.01 | 1.58E-04d | 0.62 | 5.18E-01 |
| miR-410 | 0.96 | 9.56E-01 | 0.15 | 2.33E-02c | 0.00 | 1.11E-04d |
| miR-425-5p | 1.38 | 6.57E-01 | 9.47 | 1.01E-02c | 74.46 | 4.37E-04c |
| miR-449a | 10.65 | 7.71E-03c | 15.12 | 3.52E-03c | 2.53 | 2.23E-01 |
| miR-449b | 0.79 | 7.37E-01 | 11.57 | 6.39E-03c | 21.20 | 3.13E-03c |
| miR-486 | 0.02 | 2.06E-04d | 0.01 | 9.73E-05d | 0.34 | 1.65E-01 |
| miR-489 | 0.06 | 2.73E-03c | 0.10 | 8.61E-03c | 0.25 | 8.62E-02 |
| miR-511 | 0.40 | 2.20E-01 | 0.07 | 3.72E-03c | 0.18 | 4.11E-02 |
| miR-517c | 0.07 | 3.48E-03c | 0.01 | 1.29E-04d | 0.36 | 1.82E-01 |
aRM, reduction mammoplasty; PRM, pooled reduction mammoplasty; HN, histologically normal; DCIS, ductal carcinoma in situ; microRNA in boldface type have previously been implicated in invasive breast cancer; bP value determined by Student's t-test; cP < 1.7E-02 implies significance with a false-discovery rate of 0.05; dP < 2.5E-04 implies significance after the Bonferroni correction; fold change in expression between comparisons was considered significant if P < 5E-02.